Micro-dose hCG as luteal phase support without exogenous progesterone administration: mathematical modelling of the hCG concentration in circulation and initial clinical experience

C. Yding Andersen^{1,2} · R. Fischer³ · V. Giorgione¹ · Thomas W. Kelsey⁴

Received: 19 June 2016 / Accepted: 22 June 2016 / Published online: 22 July 2016
© Springer Science+Business Media New York 2016

Abstract For the last two decades, exogenous progesterone administration has been used as luteal phase support (LPS) in connection with controlled ovarian stimulation combined with use of the human chorionic gonadotropin (hCG) trigger for the final maturation of follicles. The introduction of the GnRHa trigger to induce ovulation showed that exogenous progesterone administration without hCG supplementation was insufficient to obtain satisfactory pregnancy rates. This has prompted development of alternative strategies for LPS. Augmenting the local endogenous production of progesterone by the multiple corpora lutea has been one focus with emphasis on one hand to avoid development of ovarian hyper-stimulation syndrome and, on the other hand, to provide adequate levels of progesterone to sustain implantation. The present study evaluates the use of micro-dose hCG for LPS support and examines the potential advances and disadvantages. Based on the pharmacokinetic

characteristics of hCG, the mathematical modelling of the concentration profiles of hCG during the luteal phase has been evaluated in connection with several different approaches for hCG administration as LPS. It is suggested that the currently employed LPS provided in connection with the GnRHa trigger (i.e. 1,500 IU) is too strong, and that daily micro-dose hCG administration is likely to provide an optimised LPS with the current available drugs. Initial clinical results with the micro-dose hCG approach are presented.

Keywords Luteal phase support · Corpus luteum function · GnRH agonist trigger · hCG

Introduction

A bolus injection of human chorionic gonadotropin (hCG) has been consistently used for the final maturation of oocytes since the introduction of in vitro fertilisation (IVF) treatment and is considered the gold standard in connection with assisted reproduction techniques (ARTs). However, the hCG trigger is associated with a high risk of ovarian hyper-stimulation syndrome (OHSS) especially in high-responder patients [1–4]. Moreover, the massive stimulation of progesterone production in the early luteal phase due to the supra-physiological levels of luteinizing hormone (LH)-like activity differs profoundly from the natural progesterone profile during the luteal phase [5]. With the hCG trigger, progesterone levels peak shortly after oocyte pick up (OPU) and prior to the mid-luteal phase, when progesterone in the natural menstrual cycle reaches its peak concentration. It has been suggested that this early rise in progesterone may lead to an advancement of the endometrium and reduced implantation [6].

In recent years, the GnRH agonist (GnRHa) trigger has been used as an alternative to the hCG trigger in patients following the antagonist protocol [7–9]. The GnRHa trigger

Capsule It is suggested that the currently employed LPS provided in connection with the GnRHa trigger (i.e. 1,500 IU) is too strong, and that daily micro-dose hCG administration is likely to provide an optimised LPS with the current available drugs.

✉ C. Yding Andersen
yding@rh.dk

¹ Laboratory of Reproductive Biology, The Juliane Marie Centre for Women, Children and Reproduction, Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

² Laboratory of Reproductive Biology, Section 5712, The Juliane Marie Centre for Women, Children and Reproduction, University Hospital of Copenhagen, University of Copenhagen, Blegdamsvej 9, Rigshospitalet, 2100 Copenhagen, Denmark

³ MVZ Fertility Center Hamburg GmbH, Hamburg, Germany

⁴ School of Computer Science, University of St Andrews, St Andrews, Fife, UK

induces an endogenous surge consisting of both follicle-stimulating hormone (FSH) and LH, but at a lower magnitude of LH-like activity than that of both the hCG trigger and the area under the curve of the natural mid-cycle surge [5]. As the magnitude of the ovulation trigger is closely associated with the risk of OHSS, the GnRHa trigger combined with a 1,500-IU dose of hCG given at OPU, effectively reduces, but does not eliminate, the risk of OHSS despite multi-follicular development [3, 4]. This feature of the GnRHa trigger alone has already paved the way for a widespread use of this concept in clinical practise and especially in high-responder women, who may receive a fresh transfer or be used in connection with a freeze-all strategy [10]. The GnRHa trigger concept has found use combined with the freeze-all strategy because of low risk of OHSS and no luteal phase support (LPS) is required, and the efficacy by which oocytes complete final maturation only exhibit modest differences between the hCG trigger and the GnRHa trigger. However, many clinics do not have an optimised vitrification program and many women request a fresh transfer after a burdensome treatment and a number of clinics still focus on optimizing LPS and reducing the risk of OHSS.

One important difference between the GnRHa trigger and the hCG bolus trigger is the effect on the early luteal phase [6, 9]. In contrast to the hCG trigger, the GnRHa trigger is without stimulatory effect on the newly formed corpora lutea (CL). Thus, one pronounced characteristic of the GnRHa trigger is that it separates the two events traditionally undertaken by hCG, specifically induction of final follicular maturation and maintenance of the CL for early LPS [7–10].

The GnRHa trigger exerts a direct down-regulation of gonadotropin release from the pituitary, resulting in an insufficient amount of LH that is vital during the early luteal phase and necessary for continued function of the CL. Therefore, the GnRHa trigger used without enhanced LPS consisting of either exogenous LH-like activity or substantial progesterone supplementation yields lower pregnancy rates than the hCG trigger does [7, 11]. The lower pregnancy rates of the GnRHa trigger appear to be associated to a low mid-luteal phase progesterone level and probably reflect too low stimulation of the CL. Several studies have now suggested that in connection with ovarian stimulation (OS), the mid-luteal phase concentration of progesterone should exceed 100 nmol/l in order to reduce the risk of early pregnancy loss and augment reproductive outcome [12–14]. This concentration of progesterone is difficult to obtain through vaginal or intra-muscular administration alone and necessitates a direct stimulation of the CL with either rLH or hCG. The hCG bolus trigger lasts until shortly before the mid-luteal phase and does usually result in levels of progesterone exceeding 100 nmol/l [6]. Therefore, in order to develop the GnRHa trigger further, evaluation and understanding of the current methods for LPS are gaining interest. Based on mathematical modelling of the

pharmacokinetics of hCG, the focus of this paper is to discuss current dogmas on LPS and to suggest new ways of performing LPS including the exogenous progesterone-free concept, which recent clinical experience suggests may be performed using micro-dose daily hCG supplementation. The first clinical results using the micro-dose hCG approach will also be presented in this opinion paper.

The use of hCG for luteal phase support

The Cochrane analysis

The potential use of hCG for LPS in addition to the hCG bolus trigger has been considered as an option for many years. However, a Cochrane analysis from 2015 on LPS for ART cycles [15] found no significant effect in favour of exogenous progesterone plus hCG as compared to progesterone alone for LPS in terms of live birth or on-going pregnancy (OR 0.95 %; 95 % CI 0.65 to 1.38). This analysis found that hCG alone, or hCG plus progesterone, was associated with a higher risk of OHSS [15]. However, a modest 400 to 500 patients were in total included into this arm of the Cochrane analysis on this aspect. Further, the dose of hCG given as LPS in these studies is nowadays considered far too high. For example, in the study by Kupferminc and co-workers [16], 2500 IU hCG was given three times during the luteal phase in addition to the trigger bolus of hCG. The other studies included in the Cochrane analysis also used relatively large bolus injections of hCG two or three times during the luteal phase. By today's standard, this is a very strong LPS, and Fig. 1 illustrates the levels of hCG expected during the luteal phase calculated based on the reported half-life of hCG [17]; the average levels of hCG

Fig. 1 hCG dose of 1500 IU or 2500 IU four times. The graph represents the circulatory concentrations of hCG after exogenous hCG administration of 10,000 IU hCG followed by four administrations of either 1500 or 2500 IU of hCG during the luteal phase. Data are calculated based on the information from exogenous administration of 250- μ g recombinant hCG [17], fitted to represent a fit to a pharmacokinetic model with first-order absorption and linear elimination including a lag time

range between 40 and 80 IU/l during the entire length of the luteal phase. This is around ten times higher than the LH concentration observed during the natural menstrual cycle (i.e. 4–10 IU/l). It is therefore not surprising that the incidence of OHSS was increased. Recently, it has been shown that much lower levels of hCG can adequately support the function of the CL [6]. Even conditions observed during the natural menstrual cycle in which levels of LH remain between 4 and 8 IU/l during the entire luteal phase are sufficient to stimulate CL secretion of progesterone significantly more compared to the use of the traditional hCG trigger and vaginal progesterone [6].

Functional LH receptors on the endometrium

Furthermore, there are two lines of circumstantial experimental data that suggest, contrary to previous belief, that pharmacological levels of hCG during the early/mid-luteal phase actually may exert a negative impact on implantation.

First, the demonstration of functional LH receptor (LHR) in the endometrium with ERK 1/2 signalling in both women undergoing IVF treatment and women in their natural menstrual cycle may affect implantation [18]. Under the title “Too much of the good”, this study found that chronic exposure to normal hCG in vitro mediated a down-regulation and internalisation of LHR on endometrial epithelial cells [18]. Exposure to hCG for 3–5 days abrogated ERK 1/2 phosphorylation and attenuated adhesion to extra-cellular matrices and changes in tight junction integrity in response to an acute high dose of hCG. Endometrial epithelial LHR staining was significantly lower in women who did not become pregnant (long agonist protocol) versus the natural menstrual cycle suggesting that functional LHR signalling is of importance for facilitating implantation [18].

In connection with the clinical management of frozen embryo transfer (FET) cycles when no CL is present, the above data suggests that administration of daily micro-dose hCG just around the day of implantation (i.e. day OPU + 5 to OPU + 8) may be a possible way to augment implantation and reduce early pregnancy loss.

The molecular structure of hCG released around implantation

Another line of experimental data relate to detailed studies on the molecular structure of hCG, which have revealed several different molecular forms of hCG that appear to exert different functions [19, 20]. Especially, hyperglycosylated hCG (H-hCG) appears to play a distinct role during implantation [19]. H-hCG is a form of hCG that becomes considerably more glycosylated than normal hCG does, although the number of glycosylation sites remains similar to that of normal hCG. The increased glycosylation makes the H-hCG fold in

a way that is different from normal hCG, leading to biological properties that normal hCG does not possess. In addition to activating the LHR, the H-hCG also acts as a TGF- β antagonist [21]. When normal and H-hCG are measured during normal implantation, almost all the hCG secreted from the implanting blastocyst is H-hCG and none is normal hCG, while normal hCG only takes over later on during pregnancy. It has been suggested that it is the deficiency of H-hCG that causes incomplete blastocyst implantation or pregnancy failures, biochemical pregnancies and miscarriages [22]. It may be speculated that just when the implanting embryo starts to secrete almost exclusively H-hCG in very small quantities, the presence of normal hCG of around 40–80 IU/l (similar to those studies included in the meta-analysis of LPS; Fig. 1) attenuates successful implantation because it may interfere with the specific actions mediated by H-hCG.

The practical implication of this is that stimulation of progesterone secretion from the CL should be performed with low physiological concentrations of LH-like activity, which has recently been shown to be feasible using hCG [6] and previously using r-LH [23]. Levels of hCG associated with the use of the hCG bolus trigger level off and become very low during the mid-luteal phase, usually in the lower end of the physiological range [14]. In addition, the bolus hCG trigger elicits a progesterone peak in the early luteal phase starting to decline prior to the time of implantation.

Taken together, circumstantial evidence indicates that supra-physiological levels of hCG during the mid-luteal phase may interfere with successful implantation. Furthermore, increased concentrations of hCG augment the risk of OHSS. On the other hand, low physiological concentrations of hCG can accomplish sufficient stimulation of CL and provide support to further develop an LPS based on only micro-dose luteal phase hCG supplementation.

Results of a small RCT to test the micro-dose hCG concept for luteal phase support

In a small randomised controlled trial (RCT), the only LPS provided in the test arm was a micro-dose of hCG of 125 IU daily in connection with a GnRHa trigger. This was compared to the standard antagonist protocol using a bolus trigger of hCG for the final maturation of oocytes and LPS in the form of conventional vaginal progesterone tablets (i.e. Crinone) [6]. During the mid-luteal phase (i.e. day OPU + 7), the levels of hCG were on average twice as high in the GnRHa trigger/low-dose hCG group compared to the hCG trigger group but within the physiological range. The concentrations of progesterone were on average around twice as high in the GnRHa trigger/low-dose hCG group ($P < 0.05$). Indeed, this study demonstrated that a low physiological concentration of LH-like activity will stimulate CL sufficiently, and that supra-physiological concentrations of hCG are not necessary. In

retrospect, this is perhaps not too surprising since one CL normally produces around 30 nmol/l of progesterone during the mid-luteal phase of the natural menstrual cycle, then ten CLs may, provided that sufficient LH-like activity is present, just produce ten times more. In this respect, the physiology of the luteal phase is different from the follicular phase where FSH needs to be increased to stimulate multi-follicular development.

Local effect versus systemic effect of progesterone

The veins draining the ovary come in close contact with the uterus and the vessels leading to the uterus. Since the CL is the main source of progesterone, studies in sheep have demonstrated that the mean progesterone concentration in the ovarian vein draining a CL-containing ovary was 800-fold higher than mean jugular venous levels [24]. Furthermore, the veins from the contralateral ovary without a CL showed a mean progesterone concentration 30 times lower (ipsilateral 3297 ± 439 nmol/l; contralateral 95 ± 35 nmol/l; $P < 0.001$), showing that the local concentration of progesterone that may exert an immediate local effect on the endometrium is considerably higher than that observed in the peripheral circulation. This point is further strengthened by the observation that the mean progesterone concentration in the uterine vein was approximately 30-fold higher than in jugular vein and similar in both uterine horns [24].

Therefore, stimulation of progesterone production within CL will most likely not only increase the circulating concentration of progesterone but also augment the local effect on the uterus, which exogenous intra-muscular or subcutaneous progesterone administered will not exert. It has been claimed that vaginal progesterone tablets also exert an enhanced first pass stimulatory effect on the endometrium [25]. However, there is a rather limited amount of progesterone that can be absorbed from the vagina, and the circulatory concentration peaks 6 to 8 h after administration at a modest 35–50 nmol/l, meaning that the local uterine concentration has peaked even earlier [26]. When using vaginal progesterone pessaries, the endometrium is necessarily exposed to highly variable concentrations of progesterone. In contrast, the LH activity present in the luteal phase of natural menstrual cycle provides a far more constant exposure to progesterone; although, in this case, there are variations in the circulatory concentration of progesterone, and the fluctuations are much less pronounced [27]. It seems reasonable to expect that hCG present in similar concentrations would exert a similar effect during the luteal phase.

Taken together, the arguments are in favour of a local CL production of progesterone, which may exert a direct local effect on the endometrium and provide far higher concentrations of progesterone with just minimal stimulation rather than exogenous sources of progesterone.

Micro-dose hCG stimulation as luteal phase support

Mathematical model and validation

Various protocols have been considered in order to develop new and appropriate ways of performing LPS by use of gentle (i.e. physiological) stimulation with exogenous hCG. It is illustrative to observe the predicted course of hCG in circulation based on mathematical modelling of the pharmacokinetic information available [17]. The supplementary files show how the mathematical simulation of the hCG concentration has been performed (supplementary file). The mathematical hCG curves is obviously inferior to actual studies, which will be needed to substantiate these suggestions, but the material may help in developing protocols to be tested clinically. Nevertheless, the predicted steady-state concentration of hCG after daily administration of either 100 or 150 IU hCG as predicted by our model (Fig. 2) actually match exactly the steady-state concentration observed in a clinical study in which patients received recombinant FSH plus either 100 or 150 IU hCG daily for COS in an agonist protocol [28]. These clinical data provide an external validation of the model, but we acknowledge that generated data will provide average concentrations of hCG that require adjustment to individual patient characteristics such as weight and body composition. In the future, this highlights the ample possibilities for adjusting and individualising the dose administered.

Fig. 2 hCG doses of 100 IU, 125 IU or 150 IU daily. The graph represents the circulatory concentrations of hCG after use of the GnRHa trigger for the final maturation of follicles (devoid of hCG activity) followed by daily administration of either 100, 125 or 150 IU hCG throughout the luteal phase. The calculated concentration of hCG on day OPU + 7 is ≈ 6 IU/l, ≈ 8 IU/l, ≈ 9.5 IU/l. For data calculation, see legend to Fig. 1. Legend: OPU oocyte pick up

Fig. 3 hCG doses of 5000 IU for the final maturation of follicle followed by 500 IU at OPU + 5 (156 h). The graph represents the circulatory concentrations of hCG after exogenous hCG administration of 5000 IU hCG for final maturation of follicles followed by 500 IU hCG on day OPU + 5. The calculated concentration of hCG on day OPU + 7 is 9.4 IU/l. For data calculation, see legend to Fig. 1. Legend: OPU oocyte pick up

Reducing the traditional hCG trigger with an additional small dose of hCG on day 5 after oocyte pickup

In the case where the traditional hCG bolus trigger (i.e. 5000–10,000 IU) is used for the final maturation of oocytes, there will be a gap of LH-like activity in the mid-luteal phase around the time of implantation as previously described [6, 14]. It may be envisaged that the gap of LH-like activity can be closed by providing a continued low dose of hCG (e.g. 500 IU) just prior to the mid-luteal phase (Fig. 3). The hCG concentration will thus slightly increase and reach an average level of around 9 IU/l during the mid-luteal phase, providing continued CL stimulation until hCG produced by the pregnancy takes over. Furthermore, this approach could encourage a

Fig. 4 hCG doses of 1500 IU at OPU (36 h) and 1500 IU at OPU + 5 (156 h). The graph represents the circulatory concentrations of hCG after use of the GnRHa trigger for the final maturation of follicles (devoid of hCG activity) followed by administration of 1500 IU hCG at OPU and 1500 IU at day OPU + 5. The calculated concentration of hCG on day OPU + 7 is 23 IU/l. For data calculation, see legend to Fig. 1. Legend: OPU oocyte pick up

Fig. 5 hCG doses of 1000 IU at OPU (36 h) and 500 IU at OPU + 5 (156 h). The graph represents the circulatory concentrations of hCG after use of the GnRHa trigger for the final maturation of follicles (devoid of hCG activity) followed by administration of 1000 IU hCG at OPU and 500 IU at day OPU + 5. The calculated concentration of hCG on day OPU + 7 is 8.2 IU/l. For data calculation, see legend to Fig. 1. Legend: OPU oocyte pick up

shift from an hCG trigger of 10,000 to 5000 IU that theoretically should reduce the risk of OHSS. The exogenous level of hCG present in concentrations below 10 IU/l may only interfere with the implantation promoting the effects of H-hCG to a limited extent, since LH normally present in the circulation in similar concentrations will also bind to the LH-receptor. Furthermore, the concentration of H-hCG in the vicinity of the implanting embryo is likely to be considerably higher. This option represents a possible way to optimise the traditionally used hCG bolus trigger and is depicted in Fig. 3.

Fig. 6 hCG doses of 500 IU at OPU (36 h), OPU + 2 (84 h) and OPU + 5 (156 h). The graph represents the circulatory concentrations of hCG after use of the GnRHa trigger for the final maturation of follicles (devoid of hCG activity) followed by administration of 500 IU hCG at OPU, 500 IU at OPU + 2 plus and 500 IU at day OPU + 5. The calculated concentration of hCG on day OPU + 7 is 9.1 IU/l. For data calculation, see legend to Fig. 1. Legend: OPU oocyte pick up

Predicted curves of hCG using different micro-/low-dose protocols for luteal phase support

The overall goal for LPS using exogenous hCG administration should be to provide sufficient LH-like activity to support the secretion of appropriate progesterone levels by the CL, until the endogenous hCG from the implanting embryo takes over. So, in essence, LH-like activity provided by LH plus hCG should be in the physiological range from the time of OPU until OPU + 7/8. Different potential ways of performing LPS is given in Figs. 2, 3, 4, 5, and 6, and additionally, the predicted level of hCG 7 days after OPU at the mid-luteal phase is calculated.

In connection with the GnRHa trigger, it is necessary to provide hCG activity starting from OPU until OPU + 7/8 when the pregnancy-derived hCG takes over. The now well-established bolus dose of 1500 IU of hCG to stimulate CL function given at the time of OPU will result in hCG concentrations of around 30–50 IU/l tailing off to reach low

concentrations around the mid-luteal phase. Administering two bolus injections of 1500 IU (day OPU and day OPU + 5) in normally responding women [9] resulted in hCG levels around 40–60 IU/l during the mid-luteal phase, hence resulting in a slightly increased risk of OHSS (Fig. 4). However, as seen in Fig. 4, both the first and the second dose of 1500 IU hCG may probably be reduced without loss of sufficient stimulation of the CL.

An alternative could therefore be to reduce the dose of the bolus injection of hCG to 1000 IU on the day of OPU followed by an injection of 500 IU on day OPU + 5 (Fig. 5). This results in markedly lower concentrations of hCG, with concentrations in the physiological range around day OPU + 7. However, peak concentrations of around 25 and 15 IU/l are observed shortly after injections, which may not be necessary for sufficient CL stimulation.

The provision of three bolus injections of hCG each of 500 IU in the early/mid-luteal phase in connection with the GnRHa trigger to provide LPS has also been attempted [29].

Table 1 Reproductive outcome of IVF/ICSI treatment in women stimulated with Pergoveris (Serono, Germany) for ovarian stimulation following the antagonist protocol and receiving GnRHa trigger for the final oocyte maturation at MVZ Fertility Centre Hamburg GmbH, Hamburg, Germany

	100 IU hCG daily (1 or 2 days after OPU for 12 days)	Bolus hCG (1.500 IU) (OPU + individualized OPU 5)	<i>P</i> value
Period of treatment	June–Oct. 2015	Jan.–Oct. 2015	NA
No. of cycles/women	94/84	150/127	NA
Age (years)	36.6 ± 0.43	37.3 ± 0.33	<i>P</i> > 0.10 ^a
Days of stimulation	8.5 ± 0.12	8.5 ± 0.07	<i>P</i> > 0.10 ^a
FSH consumption (IU)	2069 ± 75	2020 ± 59	<i>P</i> > 0.10 ^a
No. of oocytes (per cycle)	9.4 ± 0.42	11.6 ± 0.55	<i>P</i> < 0.001 ^a
Normally fertilised (MII oocyte)	478/749 (64 %)	925/1411 (66 %)	<i>P</i> > 0.10 ^b
Cryopreserved: 2 PN/embryos	44/65	133/74	NA
No. of embryos for culture	328	610	NA
No. of embryos used for ET	132/80 (1.7)	234/135 (1.7)	<i>P</i> > 0.10 ^b
No. of patients receiving 1500 IU hCG × 1 or one additional hCG inj.	NA	97/53	NA
No. of patients receiving ET (% per cycle)	80 (85 %)	135 (90 %)	<i>P</i> > 0.10 ^b
No. of pos. hCG (% of ET)	44 (55 %)	72 (53 %)	<i>P</i> > 0.10 ^b
No. of clinical pregnancies (%)	42 (53 %)	59 (44 %)	<i>P</i> > 0.10 ^b
Biochemical pregnancy (%)	2/44 (4.5 %)	13/72 (18.1 %)	<i>P</i> = 0.02 ^b
Status of clinical pregnancies	3 abortions (7 %), 39 ongoing	4 births, 10 abortions (17 %), 45 ongoing	<i>P</i> = 0.09 ^c
Total losses per pregnancy	5/44 (11.5 %)	23/72 (31.9 %)	<i>P</i> = 0.003 ^c
No. of OHSS cases	1 late onset–moderate	0	NA

Luteal phase support was given as either daily low-dose hCG (100 IU/day) without exogenous progesterone or as one/two bolus injections of 1500 IU plus exogenous vaginal progesterone supplementation (800 mg progesterone vaginally; Ultragest) (second bolus hCG individualized according the number of follicles 500 or 750 or 1500 IU)(mean ± SEM). Data is from one reproductive center. All patients treated during this period received the GnRHa trigger for final maturation of follicles. Results are mean ± SEM

NA not applicable

^a Student's *t* test

^b Fisher exact probability test

^c Chi² test

This strategy results in hCG concentrations below 20 IU/l and will provide LH-like activity in the physiological range at OPU + 7. The risk of inducing OHSS should be reduced; although, this particular study actually found an OHSS rate of 3.5 % in this group with the majority being late-onset OHSS (Fig. 6). This illustrates that levels of hCG should be constantly kept in physiological window to reduce the risk of OHSS.

In order to avoid any peaks of hCG activity, one approach is to provide micro-dose hCG injections daily [27]. Based on the model, the course of hCG by daily injections of hCG (i.e. 100, 125 or 150 IU) is shown in Fig. 2. It is seen that the steady-state concentrations are around 6, 8 or 9.5 IU/l respectively, and each remains within the physiological range of LH-like activity throughout the luteal phase. It may be conceptualised that in order to obtain a quick increase in LH activity after OPU, different doses could be administered with, for instance, 150 IU for the first 2 days and then a shift to daily 100 IU doses for the rest of the LPS.

First clinical results on the use of micro-dose hCG administration for luteal phase support

Several clinics have now switched to an all GnRHa trigger approach, and one clinic has as a routine that implemented the micro-dose hCG daily LPS (i.e. 100 IU daily until a positive pregnancy test) representing clinical data in routine practice on this approach. The preliminary results of the first almost 100 patients are presented in Table 1. Both groups of patients received OS independent of the LPS provided and exhibited similar characteristics. The final maturation of oocytes was induced by a GnRHa trigger in both groups but the LPS differed; one group received a bolus of hCG of 1500 IU on the day of OPU plus in some cases an additional bolus of hCG on OPU + 5 plus exogenous vaginal progesterone supplementation, whereas the other group received a micro-dose of 100 IU hCG daily only starting 1 or 2 days after OPU.

It is noticeable that the clinical pregnancy rate is increased by 9 % in favour of the daily micro-dose hCG group and that the rate of early pregnancy loss is significantly lower despite that no exogenous progesterone is provided in the daily micro-dose hCG group. Obviously, these data needs to be taken with caution, since this is not an RCT that has controlled for potential bias, but the findings do warrant further investigations and a proper RCT.

The ultimate goal may be to develop a long-acting hCG variant in connection with the GnRHa trigger that can provide a constant low level of hCG in the physiological range throughout the luteal phase, potentially providing a new alternative LPS. This drug remains to be developed, but this analysis demonstrates that new strategies to improve reproductive outcome in IVF still remain to be explored.

Collectively, the present opinion paper suggests that revisiting the use of hCG for LPS may represent one option

to introduce the exogenous progesterone free concept and simultaneously improve reproductive outcome. It is also suggested that gentle micro-dose hCG administration for LPS is a strategy that may result in a reduced incidence of OHSS. There are multiple ways of stimulating the CL to produce high levels of progesterone, and there are ample opportunities to individualise treatment. Although the administration of micro-dose hCG in a clinical setting is still not in routine practice and requires additional instructions and preparation, it will provide better comfort and convenience to the patients, as they can avoid vaginal progesterone pessaries or painful intramuscular injections. It may be envisioned that a long-acting hCG molecule which could provide continuous physiological concentrations of hCG during the luteal phase would be the future solution.

Acknowledgments The University Hospital of Copenhagen and the EU interregional project ReproHigh/ReproUnion are gratefully acknowledged for financial support. They had no role in the study design, collection and analysis of data, data interpretation or in writing the report.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest

Ethical approval For this type of study, formal consent is not required.

Reference

1. Mathur RS, Akande VA, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. *Fertil Steril*. 2000;73:901–9.
2. Papanikolaou EG, Pozzobon C, Kolibianakis EM. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. *Fertil Steril*. 2006;85:112–20.
3. Aboulghar M. Symposium: update on prediction and management of OHSS. Prevention of OHSS. *Reprod Biomed Online*. 2009;19:33–42.
4. Papanikolaou EG, Humaidan P, Polyzos NP, Tarlatzis B. Identification of the high-risk patient for ovarian hyperstimulation syndrome. *Semin Reprod Med*. 2010;28:458–62.
5. Fauser BC, De Jong D, Loivennes F, Wramsby H, Tay C, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist Ganirelix during ovarian hyperstimulation for in vitro fertilization. *J Clin Endocrinol Metab*. 2002;87:709–15.
6. Yding Andersen C, Elbaek HO, Alsbjerg B, Laursen RJ, Povlsen BB, et al. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial. *Hum Reprod*. 2015;30:2387–95.
7. Humaidan P, Bredkjaer HE, Bungum L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. *Hum Reprod*. 2005;20:1213–20.

8. Humaidan P, Bungum L, Bungum M, Yding AC. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. *Reprod Biomed Online*. 2006;13:173–8.
9. Humaidan P, Polyzos NP, Alsbjerg B, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. *Hum Reprod*. 2013;28:2511–21.
10. Humaidan P, Kol S, Papanikolaou EG. Copenhagen GnRH Agonist Triggering Workshop Group. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? *Hum Reprod Update*. 2011;17:510–24.
11. Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. *Hum Reprod*. 2005;20:2887–92.
12. Liu HC, Pyrgiotis E, Davis O, Rosenwaks Z. Active corpus luteum function at pre-, peri- and postimplantation is essential for a viable pregnancy. *Early Pregnancy*. 1995;1:281–7.
13. Yovich JL, Conceicao JL, Stanger JD, Hinchliffe PM, Keane KN. Mid-luteal serum progesterone concentrations govern implantation rates for cryopreserved embryo transfers conducted under hormone replacement. *Reprod Biomed Online*. 2015;31:180–91.
14. Yding Andersen C, Vilbourn AK. Improving the luteal phase after ovarian stimulation: reviewing new options. *Reprod Biomed Online*. 2014;28:552–9.
15. van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. *Cochrane Database Syst Rev*. 2015;7:CD009154.
16. Kupferminc MJ, Lessing JB, Amit A, Yovel I, David MP, et al. A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in-vitro fertilization and embryo transfer. *Hum Reprod*. 1990;5:271–3.
17. Trinchard-Lugan I, Khan A, Porchet HC, Munafo A. Pharmacokinetics and pharmacodynamics of recombinant human chorionic gonadotrophin in healthy male and female volunteers. *Reprod Biomed Online*. 2002;4:106–15.
18. Evans J, Salamonsen LA. Too much of a good thing? Experimental evidence suggests prolonged exposure to hCG is detrimental to endometrial receptivity. *Hum Reprod*. 2013;28:1610–9.
19. Cole LA. hCG, five independent molecules. *Clin Chim Acta*. 2012;413:48–65.
20. Fournier T, Guibourdenche J, Evain-Brion D. hCGs: different sources of production, different glycoforms and functions. *Placenta*. 2015;36:S60–5.
21. Cole LA. hCG, the wonder of today's science. *Reprod Biol Endocrinol*. 2012;10:24.
22. Cole LA. Hyperglycosylated hCG and pregnancy failures. *J Reprod Immunol*. 2012;93:119–22.
23. Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, Devroey P, et al. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. *Fertil Steril*. 2011;95:1174–7.
24. Abecia JA, Lozano JM, Forcada F, Zarazaga L. Effect of level of dietary energy and protein on embryo survival and progesterone production on day eight of pregnancy in Rasa Aragonesa ewes. *Anim Reprod Sci*. 1997;48:209–18.
25. Levine H, Watson N. Comparison of the pharmacokinetics of crinone 8 % administered vaginally versus prometrium administered orally in postmenopausal women. *Fertil Steril*. 2000;73:516–21.
26. Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, et al. Direct transport of progesterone from vagina to uterus. *Obstet Gynecol*. 2000;95:403–6.
27. Filicori M, Butler JP, Crowley Jr WF. Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion. *J Clin Invest*. 1984;73:1638–47.
28. Thuesen LL, Loft A, Egeberg AN, Smits J, Petersen JH, Andersen AN. A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization. *Hum Reprod*. 2012;27:3074–84.
29. Castillo JC, Dolz M, Bienvenido E, Abad L, Casañ EM, et al. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support. *Reprod Biomed Online*. 2010;20:175–81.